These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19028807)

  • 1. Family tracing to identify patients with familial hypercholesterolaemia: the second audit of the Department of Health Familial Hypercholesterolaemia Cascade Testing Project.
    Hadfield SG; Horara S; Starr BJ; Yazdgerdi S; Marks D; Bhatnagar D; Cramb R; Egan S; Everdell R; Ferns G; Jones A; Marenah CB; Marples J; Prinsloo P; Sneyd A; Stewart MF; Sandle L; Wang T; Watson MS; Humphries SE;
    Ann Clin Biochem; 2009 Jan; 46(Pt 1):24-32. PubMed ID: 19028807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are patients with familial hypercholesterolaemia well managed in lipid clinics? An audit of eleven clinics from the Department of Health Familial Hypercholesterolaemia Cascade Testing project.
    Hadfield SG; Horara S; Starr BJ; Yazdgerdi S; Bhatnagar D; Cramb R; Egan S; Everdell R; Ferns G; Jones A; Marenah CB; Marples J; Prinsloo P; Sneyd A; Stewart MF; Sandle L; Wang T; Watson MS; Humphries SE
    Ann Clin Biochem; 2008 Mar; 45(Pt 2):199-205. PubMed ID: 18325186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.
    Nherera L; Marks D; Minhas R; Thorogood M; Humphries SE
    Heart; 2011 Jul; 97(14):1175-81. PubMed ID: 21685482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK.
    Kerr M; Pears R; Miedzybrodzka Z; Haralambos K; Cather M; Watson M; Humphries SE
    Eur Heart J; 2017 Jun; 38(23):1832-1839. PubMed ID: 28387827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
    Marks D; Wonderling D; Thorogood M; Lambert H; Humphries SE; Neil HA
    Health Technol Assess; 2000; 4(29):1-123. PubMed ID: 11109029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes.
    Marks D; Thorogood M; Neil SM; Humphries SE; Neil HA
    J Med Screen; 2006; 13(3):156-9. PubMed ID: 17007658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of child-parent screening and cascade testing for familial hypercholesterolaemia.
    Wald DS; Wald NJ
    J Med Screen; 2019 Jun; 26(2):71-75. PubMed ID: 30319009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Census of clinics providing specialist lipid services in the United Kingdom.
    Marks D; Thorogood M; Farrer JM; Humphries SE
    J Public Health (Oxf); 2004 Dec; 26(4):353-4. PubMed ID: 15598852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study of universal screening of children and child-parent cascade testing for familial hypercholesterolaemia in Australia.
    Martin AC; Hooper AJ; Norman R; Nguyen LT; Burnett JR; Bell DA; Brett T; Garton-Smith J; Pang J; Nowak KJ; Watts GF
    J Paediatr Child Health; 2022 Feb; 58(2):281-287. PubMed ID: 34387892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
    McKay AJ; Hogan H; Humphries SE; Marks D; Ray KK; Miners A
    Atherosclerosis; 2018 Aug; 275():434-443. PubMed ID: 29937236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.
    Pelczarska A; Jakubczyk M; Jakubiak-Lasocka J; Banach M; Myśliwiec M; Gruchała M; Niewada M
    Atherosclerosis; 2018 Mar; 270():132-138. PubMed ID: 29407882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reaching detection targets in familial hypercholesterolaemia: Comparison of identification strategies.
    Wald DS; Bestwick JP
    Atherosclerosis; 2020 Jan; 293():57-61. PubMed ID: 31837509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homozygous familial hypercholesterolaemia in Vietnam: Case series, genetics and cascade testing of families.
    Truong TH; Kim NT; Nguyen MNT; Pang J; Hooper AJ; Watts GF; Do DL
    Atherosclerosis; 2018 Oct; 277():392-398. PubMed ID: 30270076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tracing of patients with familial hypercholesterolemia in the Netherlands].
    Umans-Eckenhausen MA; Defesche JC; Scheerder RL; Cliné F; Kastelein JJ
    Ned Tijdschr Geneeskd; 1999 May; 143(22):1157-61. PubMed ID: 10371839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience.
    Bell DA; Pang J; Burrows S; Bates TR; van Bockxmeer FM; Hooper AJ; O'Leary P; Burnett JR; Watts GF
    Atherosclerosis; 2015 Mar; 239(1):93-100. PubMed ID: 25585028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cascade testing of children and adolescents for elevated Lp(a) in pedigrees with familial hypercholesterolaemia.
    Loh WJ; Pang J; Chakraborty A; Ward NC; Chan DC; Hooper AJ; Bell DA; Burnett JR; Martin AC; Watts GF
    J Clin Lipidol; 2024; 18(1):e33-e37. PubMed ID: 38040538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy.
    Descamps OS; Rietzschel E; Laporte A; Buysschaert I; De Raedt H; Elegeert I; Chenot F; Lengele JP; Carlier S; Vanderheeren P; Lienart F; Friart A; Guillaume M; Vandekerckhove H; Maudens G; Mertens A; van de Borne P; Bondue A; De Sutter J
    Acta Cardiol; 2021 May; 76(3):227-235. PubMed ID: 32964780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening.
    Marks D; Thorogood M; Neil HA; Wonderling D; Humphries SE
    J Public Health Med; 2003 Mar; 25(1):47-52. PubMed ID: 12669918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the identification of patients with a genetic diagnosis of familial hypercholesterolaemia in primary care: A strategy to achieve the NHS long term plan.
    Ingoe L; Potter A; Musson S; Neely D; Pilkington G; Allen AJ; Reay D; Luvai A; McAnulty C; Camm N; Berry I; Nichols J; Forbes G; Newton J; Carey PE
    Atherosclerosis; 2021 May; 325():38-45. PubMed ID: 33892327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic testing increases the likelihood of a diagnosis of familial hypercholesterolaemia among people referred to lipid clinics: Danish national study.
    Hedegaard BS; Bork CS; Kanstrup HL; Thomsen KK; Heitmann M; Bang LE; Henriksen FL; Andersen LJ; Gohr T; Mouridsen MR; Soja AMB; Elpert FP; Jakobsen TJ; Sjøl A; Joensen AM; Nordestgaard BG; Klausen IC; Schmidt EB
    Atherosclerosis; 2023 May; 373():10-16. PubMed ID: 37080006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.